Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
MICHAEL HENKE, MD PHD office private Klinik fuer Strahlenheilkunde, Radiologische Universitaetsklinik Robert-Koch-Strasse 3 D-79106 Freiburg i.Br. - Germany Tel (Fax): 0761/270-95500 (94970); [email protected] Auf der Haid 65, D-79114 Freiburg i.Br. - Germany; 0761/493769 CURRENT APPOINTMENTS Senior Consultant, Associate Professor and Head of Clinical Research Section, Dep. for Radiation Oncology, University Clinic Freiburg PREVIOUS APPOINTMENTS / TRAINING 1978 1979 1980 1982 1984 1991 1992 2004 Postdoctoral-fellow, Institute for Pathology, University Würzburg Postdoctoral-fellow, Clinic for Radiation Oncology and Nuclear Medicine, University Zürich Postdoctoral-fellow, Dep. Cardiology, Pulmonology and Nephrology, Medical University Clinic, Tübingen Clinical fellow and Senior Research Scientist, Bone marrow Transplantation Unit, City of Hope Medical Center, Duarte, California Staff member, Dep. Hematology/Medical Oncology, Medical University Clinic, Freiburg Staff member – supervising physician, Krankenhaus der Barmherzigen Brüder, Trier Staff member – supervising physician, Dep. for Radiation Oncology, Radiological University Clinic, Freiburg Section head, Dep. for Radiation Oncology, Radiological University Clinic, Freiburg EDUCATION 1978 1989 1989 1991 1995 2001 2005 MD; PhD-Thesis, Faculty of Medicine, Freiburg University; license to practice medicine, Reg. Präsidium Stuttgart Board certificate: Internal Medicine Board certificate: Hematology/Medical Oncology Board certificate: Rheumatology Board certificate: Radiation Oncology Habilitation / venia legendi „Radiooncology und Radiation Treatment“, Faculty of Medicine, Freiburg University Associate Professor TEACHING EXPERIENCE 1978 –1979 Histopathology Seminar for Medical Students Michael Henke CV 1979 –1980 1980 - 1982 1985 –1988 1991 1992 – 1992 – 1996 – 1998 – 2 Nuclear Medizin and Radiotherapy Course for Medical Students Physical Examination Course for Medical Students Hematology Seminar for Medical Students Diagnosis and Treatment of Rheumatologic Disease- Seminar for Residents Internal Medicine/ Medical Oncology Lecture for Medical Students Introduction to Radiation Oncology Lecture for Medical Students Diagnosis and Treatment in Oncology- bed side teaching for Residents Radiation Oncology for Localized Cancer Lecture for Medical Students SCIENTIFIC FOCUS - Phase II/III (registration-relevant) trials (pharmacological modification of radiosensitivity/protection). - Phase I/II bench to bedside studies (targeted changes of signal transduction in combination with radiation). - Bed to bench research (mechanisms of clinical observations; radiosenzitation/protection) - Head&neck cancer / lung cancer / GI cancer / multimodal treatment. AWARDS 2004 2004 ARO Study Award for outstanding clinical research Eleonore and Fritz Hodeige Award for innovative clinical research MEMBERSHIPS Bund Deutscher Internisten (BDI) Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO) Arbeitsgemeinschaft Knochenmarktransplantation Deutsche Gesellschaft für Radioonkologie (DEGRO) European Society for Therapeutic Radiology and Oncology (ESTRO) REVIEWER FOR Lancet Nature Journal of the National Cancer Institute Radiotherapy and Oncology Strahlentherapie&Onkologie Annals of Hematology Clinical Cancer Research Onkologie Respiratory Medicine Neoplasia Michael Henke CV 3 CONSULTANT FOR Roche Pharma; Johnson&Johnson/Orthobiotech; Amgen; Lilly Pharma COOPERATIONS - National and international clinical study groups in radiation oncolgy (see funding and publications below) - Dep. of Hematology, Fred Hutchinson Cancer Research Center; Seattle - Department of Radiation Oncology, David Geffen School of Medicine at UCLA Los Angeles - Gesellschaft für Strahlenforschung, München - Center for Clinical Research and Center for Clinical Studies (University Freiburg) - Dep. Diagnostic Radiology, Freiburg Radiological University Clinic, Dep. Hemato/Oncology, Freiburg Medical University Clinic; Freiburg University Clinic for Head&Neck Disease, Dep. Thoraxic Oncology, Freiburg Surgical University Clinic, Dep. Abdominal Surgery, Freiburg Surgical University Clinic - Institute for Pathology, University Freiburg MANAGEMENT 1984 - today head of clinical & research teams covering responsibilities for clinical & scientific conduct, personnel and budget 1986 - 1988 responsible for clinical conduct an structural establishment of the Freiburg „bone marrow transplantation program“, including personnel and budget 1991 – today supervising physician 2001 – 2004 vice chair of department 1995 – today head of clinical research group (since 2004 section) with responsibilities for clinical & scientific conduct, structural development, personnel and budget Michael Henke CV FUNDING / CLINICAL STUDIES German Research Foundation/ Cancer Society 1982 - 1984 Antigranulocytic Antibodies; DFG He 1286/1-1 and 2 1986 – 1989 Oncogeneproducts; DFG He 1286/2-1/2 1989 Autologous Bone Marrow Transplantation; Deutsche Krebshilfe M 31/87/ He1 Intramural 1993 – 1994 Nitric Oxide in Human Cancer Cells 1994 – 1996 Oxygenation and Radiosensitivity of Human Cancer Industrial 1994 – 1996 Erythropoietin for Anemic Patients undergoing Radiation Treatment – Phase II/III Feasibility Study; Cilag 1997 – 1998 Phase-II Randomized Study Investigating Safety, Feasibility and Efficacy of Metoclopramide as Radiosensitizer for Non Small Cell Lung Cancer; Oxygene 1997 – 2001 Randomized, Doubleblind, Multicenter Study to Investigate the Effect of 7-9 Weeks Epoetin-beta Treatment on Locoregional Tumorcontrol of Head and Neck Cancer Patients (ARO-98-2); Boehringer/Roche 1997 – 1998 Randomized phase-III trial of radiation-therapy +/- amifo-stine in patients with head and neck cancer (WR-38); USB 1998 – 2000 Clinical study phase-II to investigate the effect of "RP-971ST" on prophylaxis of skin damage due to radiotherapy (RP-970015)); Regenold 2000 - 2006 Phase-I Study: Radiochemotherap (XRT, Cisplatin and Gemcitabine) for Patients with Non Small Cell Lung Cancer, III A/B; Lilly 2001 –2006 Multinational, multicenter, double blind, placebo-con-trolled, randomized, phase- III clinical trial to determine the efficacy and safety of IB-367 Rinse in reducing the severity of oral mucositis in patients receiving radiotherapy for head and neck malignancy; Intrabiotics Pharma 2001 – 2002 Phase-3 randomized, open-label comparative study of standard whole brain radiation therapy with or without "RSR 13" in patients with brain metastases (RSR13 RT-009); Allos 2003 – 2005 Phase-III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer (EFC 4690); Sanofi 2002 - 2004 Phase-IV Study on Efficacy and Compliance of Zometa in Patients undergoing Radiation for advanced osteolytic bone metastases. (ZOL-RTX1); Novartis 4 Michael Henke CV 2002 – 2005 Phase-II Study: oral Vinorelbin and Cisplatin as Inductiontherapy and Concommittant to Radiotherapy for limited Non Small Cell Lung Cancer; Pierre Fabre 2005 - 2007 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy (RT/CT); Amgen; 20020118 2005 - 2006 Phase III randomized trial of concomitant radiation, cisplatin and tirapazamine (SR 259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer (EFC 5512); Sanofi 2005 - 2007 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy with Concurrent Chemotherapy (RT/CT) Amgen; 20020402 2008 - 2009 A Phase 3, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected. Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Amgen 20062080) 2009 - 2009 A randomized, double-blind, parallel group phase III clinical study to assess the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on oral mucostitis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy 2009-2010 A Phase 3, randomized trial of chemoradiation with 5-Fluorouracil plus Oxaliplatin compared with a preoperativen chemoradiation with 5Fluorouracil (local advanced Rectumcancer UICC-Stadium II /III ) 2009-2011 Multicenter, open-label phase II trial on post-surgery chemoradiation in bombination with cetuximab in squamous cell carcinoma or the head and neck with high risk of loco regional recurrence (ACCRA-HN-Studie) SELECTED PUBLICATIONS 5 Michael Henke CV 6 Rischin D, Peters L, O´Sullivan B, Giralt J, Yuen K, Trotti A, Bernier J, Bourhis J, Henke M, Fisher R: Phase III study of tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol, 2010, 28 (18): 2989-2995. Momm F, Kaden M, Tannock I, Schumacher M, Hasse J, Henke M: Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study. Cancer, 2010; 116 (20): 4833-4839. Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA: Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase III Clinical Trial. Stem Cells. 2009; 27(9):2353-61 . Bauer VL, Braselmann H, Henke M, Mattern D, Walch A, Unger K, Baudis M, Lassmann S, Huber R, Wienberg J, Werner M, Zitzelsberger HF: Chromosomal changes characterize head and neck cancer with poor prognosis. J Mol Med. 2008; 86(12):1353-65. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P: Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol. 2008; 3(9):994-1002. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008 299:914-24. Rischke HC, Momm F, Henke M, Wiech T, Frommhold H: Does radiation prevent 5fluorouracil-induced colitis in the early phase of radiochemotherapy? A case report and literature review. Strahlenther Onkol. 2007; 183(8):459-63. Ghanem N, Lerche A, Lohrmann C, Altehoefer C, Henke M, Langer M: Quantitative and semiquantitative evaluation of erythropoietin-induced bone marrow signal changes in lumbar spine MRI in patients with tumor anemia. Onkologie. 2007; 30(6):303-8. Henke M., Mattern D., Pepe M., Bézay C., Weissenberger C., Werner M., Pajonk F.: Do Erythropoietin Receptors On Cancer Cells Explain Unexpected Clinical Findings? J Clin Oncol 2006; 24(29): 4708–13. Henke M., Verma A., Acs G.: Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate. Blood 2006; 108(3): 1107-9. Momm F, Schafer O, Henke M.: Metastatic breast cancer causing gas gangrene. J Pain Symptom Manage. 2006; 31(5):385 Becker G, Momm F, Xander C, Bartelt S, Zander-Heinz A, Budischewski K, Domin C, Henke M, Adamietz IA, Frommhold H.: Religious belief as a coping strategy: an explorative trial in patients irradiated for head-and-neck cancer. Strahlenther Onkol. 2006;182(5):270-6. Weissenberger C, Geissler M, Otto F, Barke A, Henne K, von Plehn G, Rein A, Muller C, Bartelt S, Henke M.: Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (19892002). World J Gastroenterol. 2006; 12(12):1849-58. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V.: Influence of Michael Henke CV 7 intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for headand- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005; 63(4): 985-90. Henke M.: Erythropoietin in the treatment of cancer. Onkologie. 2005; 4:181-2 Pajonk, F., Weil, A., Sommer, A., Suwinski, R., Henke, M.: The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene. 2004; 23(55): 8987-91 Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T.F., Fleming, T.R., Henke, M., Bourhis, J., Rosenthal, D.I., Junor, E., Cmelak, A., Sheehan, F., Pulliam. J., Devitt-Risse, P., Fuchs, H., Chambers, M., O'Sullivan, B., Ang, K.K.: A multinational, randomized phase III trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck-malignancy. Int J Radiat Oncol, 2004; 58 (3) : 674-681 Schipper, J., Henke, M.: Erythropoietin in patients with head and neck carcinomas? Laryngo Rhino Otol, 2004; 83 (5) : 292-297 Henke, M.: Erythropoietin and Curative Cancer Treatment. The American Journal of Oncology Review, 2004; 3 (4) : 190-192 Fritzsche, K., Liptai, C., Henke, M.: Psychosocial distress and need for psychotherapeutic treatment in cancer patients undergoing radiotherapy Radiother Oncol, 2004; 72: 183-189 Brink, I., Schumacher, T., Mix, M., Ruhland, S., Stoelben, E., Digel, W., Henke, M., Ghanem, N., Moser, E., Nitzsche, E.U.: Impact of [(18)F] FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol I, 2004 Henke, M., Sindlinger, F., Ikenberg, H., Gerds, T., Schumacher, M.: Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol, 180:45-51, 2004 Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T.F., Fleming, T.R., Henke, M., Bourhis, J., Rosenthal, D.I., Junor, E., Cmelak, A., Sheehan, F., Pulliam, J., Devitt-Risse, P., Fuchs, H., Chambers, M., O'Sullivan, B., Ang, K.K.: A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys, 58:674-581, 2004 Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K-D, Schilcher, B., Mose, S., Beer, K., Burger, U., Dougherty, C., Frommhold H.: Erythropoietin to treat head and neck cancer patients with anaemia: randomised, double-blind, placebo-controlled trial. Lancet, 362:12551260, 2003 Momm, F., Weißenberger, C., Bartelt, S., Henke, M: Moist skin care can diminish acute radiaton-induced skin toxicity. Strahlenther Onkol, 179:708-712, 2003 Pajonk, F, Weissenberger, C., Witucki, G., Henke, M: Vitiligo at sites of irradiation in a patient with Hodgkin´s disease. Strahlenther Onkol, 178:159-162, 2002 Momm, F., Bechtold, C., Rudat, V., Strnad, V., Tsekos, A., Fischer. K,, Henke, M.: Alteration of radiation-induced hematotoxicity by amifostine. Int J Radiat Oncol Biol Phys, 51: 947-951, 2001 Schumacher, T., Brink, I., Mix, M., Reinhardt, M., Herget, G., Digel, W., Henke, M., Moser, E., Nitzsche, E.: FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med, 28:483-488, 2001 Pajonk, F., Schlessmann, S., Guttenberger, R., Henke, M.: Epithelial cells in the peripheral blood Michael Henke CV 8 of patients with cancer of the head and neck: incidence, detection and possible clinical significance. Radiother Oncol, 59:213-217, 2001 Brizel, D.M., Wasserman, T.H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., Sauer, R.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 18, 3339-3345, 2000 Rudat, V., Meyer, J., Momm, F., Bendel, M., Henke, M., Strnad, V., Grotz, K., Schulte, A.: Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys, 48, 1339-1343, 2000 Henke, M., Bechtold, C., Momm, F., Dörr, W., Guttenberger, R.: Blood Hemoglobin Level May Affect Radiosensitivity – Preliminary Results on Acutely Reacting Normal Tissues. Int J Radiat Oncol Biol Phys, 48, 339-345, 2000 Momm, F., Bechtold, C., Fischer, K., Tsekos, A., Henke, M.: Alteration of radiation-induced hematotoxicity by amifostine. Strahlenther Onkologie 175, 2-5, 1999 Henke, M., Guttenberger, R., Barke, A., Pajonk, F., Pötter, R., Frommhold, H.: Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiotherapy Oncology, 50, 185-190, 1999 Frommhold, H., Guttenberger, R., Henke, M.: The impact of blood hemoglobin content on the outcome of radiotherapy: The Freiburg experience. Strahlenther Onkologie, 174, 31-34, 1998 Jonas, D., Lubbert, M., Kawasaki, E.S., Henke, M., Bross, K.J., Mertelsmann, R., Herrmann, F: Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood, 79, 1017-1023, 1992 Freund, M., Diedrich, H., Ganser, A., Gramatzki, M., Heil, G., Heyll, A., Henke, M., Hiddemann, W., Haas, R., Kuse, R., Koch, P., Link, H., Maschmeyer, G., Planker, M., Queißer, W., Schadeck-Gressel, C., Schmitz, N., vonVerschuer, U., Wilhelm, S., Thiel, E., Hölzer, D.: Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer, 69, 709-716, 1992 Glatt, E., Henke, M., Sigmund, G., Costabel, U.: Zyklophosphamid- induzierte Pneumonitis. Fortschr Röntgenstr, 148, 545-549, 1988 Hecht, Th., Henke, M., Schempp, W., Bross, K.J., Löhr, G.W.: Acute lymphoblastic leukemia in adult identical twins. Blut 56:261-264, 1988 Henke, M., Santos, S., Winberg, C.D., Shively, J.E.: A monoclonal antibody to the heavy chain of human IgM with a particular reaction pattern in human B-cell malignancies. Blut, 55, 173-179, 1987 Henke, M., Engler, H., Engelhardt, R., Löhr, G.W.: Successful therapy of sarcoidosis-associated thrombocytopenia refractory to corticosteroids by a single course of human gammaglobulins. Klin Wochenschr, 64, 1209-1211, 1986 Münsch, H., Hecht, Th., Winkler, K.J., Gaidulis, L., Henke, M., Blume, K.G.: A monoclonal antibody to hemoglobin F. Blut, 49, 203-211, 1984 Henke, M., Yonemoto, L.M., Lazar, G.M., Gaidulis, L., Hecht, Th., Santos, S., Blume, K.G.: Visual detection of granulocyte surface antigens using the avidin-biotin complex. J Histochem Cytochem, 32, 712-716, 1984 Lazar, G.M., Gaidulis, L., Henke, M., Blume, K.G.: A sensitive screening method of detecting anti-granulocyte antibodies employing radiolabelled staphylococcal protein A. J Imm Meth, 68, 1-9, 1984 Spruce, W.E., Forman, S.J., Krance, R.A., Farbstein, M.J., Wolf, J.L., Scott, E.P., Nademanee, Michael Henke CV 9 A.P., Fahey, J.L., Henke, M., Blume, K.G.: Outcome of bone marrow transplantation patients with extramedullary involvement of acute leukemia. Blut, 48, 75-79, 1983 Metz, J., Amschler, A., Henke, M.: Degos’sche Erkrankung (malignant atrophic papulosis). Hautarzt, 31: 108-10, 1980 Henke, M., Metz, J.: Degos'sche Erkrankung - Gefäßbefunde einer seltenen Endangiopathie. Med Welt, 31, 1052-1055, 1980 LETTERS Henke, M., Laszig, R., Frommhold H.: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet, 363:81-82, 2004 Henke, M., Pajonk, F.: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet, 363:993, 2004 Frommhold, H., Henke, M.: Adjuvante Therapie bei kolorektalen Carcinomen. Dtsch Med Wschr, 120:777-779, 1995 REVIEWS Henke, M.: Clinical trials using rhEPO in radiation oncology. In Nowrousian MR (ed): Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Scientific and Clinical Aspects of Anemia in Cancer. Springer-Verlag Wien, New York; pp:301-312, 2002 Henke, M., Pajonk, F.: Experimentelle Therapieansätze. In Böttcher HD, SeifertV, Henke M, Mose St (eds): Klinik der hirneigenen Tumoren und Metastasen. Grundlagen, Diagnostik, Therapie. W. Zuckschwerdt Verlag GmbH, München, Wien, New York; pp:170-177, 2002 Henke, M.: Correction of cancer anemia - impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie, 24:450-454, 2001 Henke, M.: Biomodulation der Strahlenreaktion. In Böttcher HD, Kaufmann R, Henke M (eds): Klinik des Rezidiv-Tumors im Kopf-Hals-Bereich. Grundlagen, Diagnostik, Therapie. W. Zuckschwerdt Verlag GmbH, München, Wien, New York; pp:105-117, 2000 Henke, M.: Achievements with recombinant erythropoietin in radiotherapy. In Boiron M, Marty M (eds): Eurocancer 2000. John Libbey Eurotext, Paris; pp:57-58, 2000 Henke, M., Guttenberger, R.: Erythropoietin in radiation oncology - A review. 1st international conference, Freiburg, June 11-12. 1999. Oncology, 58, 175-182, 2000 Henke, M., Momm, F., Guttenberger, R.: Erythropoietin for patients undergoing radiotherapy. The Freiburg experience. in Vaupel P, Kelleher DK (eds). Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart: Wissenschaftliche Verlagsgesellschaft; pp 91-97, 1999 Eschwege, F., Sauer, R., Wannenmacher, M., Wassermann, T., Henke, M., Monier, A., Brizel, D.: Étude randomisée de phase III comparant irradiation avec ou sans amifostine chez des patients porteurs de tumeurs de la tête et du cou. In Lubionsky B: Cancers des voies aérodigestives supérieurs. L’avant et l’après traitement. Quel bilan? Quel suivi? EDK, Paris; pp:128-130, 1999 Guttenberger, R., Henke, M., Frommhold, H.: Erythropoietin – a radiosensitizer? in: H.D. Kogelnik, F. Sedelmayer: Progress in Radio-Oncology VI. Monduzzi Editore, Bologna; pp:223-226, 1998 Michael Henke CV 10 Henke, M., Pajonk, F., Barke, A.: Strahlenbehandlung von Knochenmetastasen Entscheidungsbasis: Wünsche des Patienten an die Lebensqualität. Krankenhaus Arzt, 70:443445, 1997 Henke, M., Bross, K.J.: Haematologie. in Droste C, vonPlanta M (eds): Memorix, Konstanten der klinischen Medizin, VCH Verlagsgesellschaft mbH Weinheim. pp:207-230 and pp:231-240, 1993 Leder, G.H., Henß, H., Henke, M., Engler, H., Fiebig, H.H., Löhr, G.W., Arnold, H.: Neopterin in the monitoring of cancer patients treated with a standardized liver- and spleen-extract. in Kuhlmann J, Wingender (eds): Dose-response relationship of drugs, Zuckschwerdt Verlag München Bern Wien San Francisco. pp:201-206, 1990 Henke, M., Hecht, Th., Löhr, G.W.: Myelopoietic reconstitution following autologous bone marrow transplantation. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin Heidelberg. pp:702-706, 1990 Freund, M., DeBoben, M., Diedrich, H., Ganser, A., Heil, G., Heyll, A., Henke, M., Hiddemann, W., Hölzer, D., Koch, P., Küchler, R., Link, H., Maschmeyer, G., Planker, M., Renner, D., Schmitz, N.: Treatment of relapsed acute lymphocytic leukemia in adults. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin Heidelberg. pp:432-436, 1990 Link, H., Freund, M., Diedrich, H., Wilke, H., Austein, J., Henke, M., Wandt, H., Fackler-Schwalbe, E., Schlimock, G., Hoffmann, R., Calavrezos, A., Poliwoda, H.: Mitoxantrone, cytosine-arabinoside and VP-16 (MAV) in 36 patients with relapsed and refractory acute myeloid leukemia. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin Heidelberg. pp:322-325, 1990 Ehninger, G., Fackler-Schwalbe, E., Freund, M., Heil, G., Henke, M., Hölzer, D., Hoffmann, R., Kurrle, E., Link, H., Lösch, A., Mitrou, P.S., Queißer, W., Schlimok, G., Wandt, H. (Süddeutsche Hämoblastosegruppe): Combination of mitoxantrone and etoposid in patients aged over 60 years with untreated acute myelogenous leukemia. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin Heidelberg. pp:316-317, 1990 Hecht, Th., Arnold, H., Henke, M.,: Spättoxizität nach der Therapie maligner Hodentumoren. in: Schmoll HJ, Weißbach L (eds): Therapie von Hodentumoren, Springer Verlag Heidelberg. pp:510-516, 1988 Löhr, G.W., Hecht, Th., Henke, M.,: Therapiekonzepte zur Behandlung von Patienten mit akuten Leukämien. In Hilgarth M und Mönig-Schuth M (eds): Festschrift. Konstanzer Verlagsanstalt. pp:277-293, 1988 Blume, K.G., Forman, S.J., Krance, R.A., Henke, M., Findley, D.O., Hill, R.A.: Bone marrow transplantation for acute leukemia. in: Neth R, Gallo RC, Greaves MF, Janka G (eds): Modern trends in human leukemia VI, Springer Verlag Berlin-Heidelberg, pp:39-41, 1985 Henke, M., Yonemoto, L.M., Lazar, G.M., Blume, K.G.: Immunoenzymatic detection of blood cell surface antigens using the avidin-biotin complex. in: Avrameas S, Druet A, Masseyeff R, Feldmann G (eds): Immunoenzymatic techniques, Elsevier Science Publ, Amsterdam, pp:41-44, 1984 Michael Henke CV ABSTRACTS More than 120 published 11